抗凝药的使用模式和癌症患者心房的癌症患者死亡的所有原因
Xu Han1, Xiaolei Yang2, Tesfaldet H Hidru2
1Health Management Center, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China.
概括
在患有心房动 (AF) 的癌症患者中,抗凝药治疗通常处方不足. 然而,抗凝剂 (AC) 的使用与这种高风险人群的死亡风险降低有关.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对抗凝血剂 (AC) 治疗对患有心房 (AF) 的癌症患者的临床益处存在不确定性.
- 评估AC使用模式及其对该人口死亡率的影响至关重要.
研究的目的:
- 评估心房动的癌症患者的抗凝剂处方率和模式.
- 为了确定抗凝剂治疗对该患者群体全因死亡率的影响.
主要方法:
- 对1,653名患有AF的癌症患者进行了回顾性队列分析.
- 多变量逻辑回归确定了AC处方的预测因素.
- 卡普兰-梅尔曲线和考克斯比例危险模型评估了生存结果.
主要成果:
- 超过一半 (58.7%) 的患者没有接受AC处方,即使是那些高中风险的患者.
- 处方AC与所有原因死亡风险明显降低相关 (HR,0.78;95% CI,0.66-0.91).
- 里瓦罗克萨班和华法林是最常见的抗凝药.
结论:
- 在患有AF的癌症患者中,抗凝剂的处方是次优的.
- 出院时的AC处方与改善的生存结果有关,这突显了它的重要性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
708
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
708
Cancer Survival Analysis
355
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
355
Disorders of Hemostasis
922
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
922


